Farmers Trust Co. Purchases 3,767 Shares of Kenvue Inc. (NYSE:KVUE)

Farmers Trust Co. grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 217,218 shares of the company’s stock after buying an additional 3,767 shares during the quarter. Farmers Trust Co.’s holdings in Kenvue were worth $4,638,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Leo Wealth LLC lifted its position in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the period. Alerus Financial NA grew its stake in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares during the period. Massmutual Trust Co. FSB ADV lifted its stake in Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares during the period. Wolff Wiese Magana LLC boosted its holdings in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after buying an additional 501 shares during the last quarter. Finally, Marathon Capital Management grew its position in shares of Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after buying an additional 514 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE remained flat at $21.05 during trading on Wednesday. The stock had a trading volume of 4,460,462 shares, compared to its average volume of 7,644,690. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock has a market capitalization of $40.36 billion, a price-to-earnings ratio of 38.27, a price-to-earnings-growth ratio of 2.02 and a beta of 1.46. The stock has a fifty day moving average price of $22.73 and a two-hundred day moving average price of $21.56.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter last year, the company earned $0.31 earnings per share. The company’s revenue for the quarter was down .4% on a year-over-year basis. Sell-side analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.90%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several research analyst reports. Barclays raised Kenvue to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.09.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.